TRAIL is a pro-apoptotic cytokine believed to selectively kill cancer cells without harming normal ones. However, we found that in normal human prostate epithelial cells (PrEC) TRAIL is capable of inducing apoptosis as eciently as in some tumor cell lines. At the same time, TRAIL did not cause apoptosis in several other human primary cell lines: aorta smooth muscle cells, foreskin ®broblasts, and umbilical vein endothelial cells. Compared to these primary cells, PrEC were found to contain signi®cantly fewer TRAIL receptors DcR1 and DcR2 which are not capable of conducting the apoptotic signal. This result suggests that the unusual sensitivity of PrEC to TRAIL may result from their de®ciency in antiapoptotic decoy receptors. The protein synthesis inhibitor cycloheximide signi®cantly enhanced TRAIL toxicity toward PrEC as measured by tetrazolium conversion but had little or no eect on other TRAIL-induced apoptotic responses. Although cycloheximide did not further accelerate the processing of caspases 3 and 8, it signi®cantly enhanced cleavage of the caspase 3 substrate gelsolin, indicating that in PrEC a protein(s) with a short half-life may inhibit the activity of the executioner caspases toward speci®c substrates. As the majority of prostate cancers are derived from epithelial cells, our data suggest the possibility that TRAIL could be a useful treatment for the early stages of prostate cancer. Oncogene (2002) 21, 1135 ± 1140. DOI: 10.1038/sj/onc/ 1205151 Keywords: TRAIL; apoptosis; primary; prostate; human TRAIL (TNFa-Related-Apoptosis-Inducing-Ligand)/ Apo-2 ligand (Wiley et al., 1995; Pitti et al., 1996) , is a pro-apoptotic cytokine that together with three related proteins, TNFa, CD95/FasL and TWEAK/Apo3L constitute a family of ligands that transduce death signals through death domain containing receptors (SchulzeOstho et al., 1998) . TRAIL has been reported to induce apoptosis in a variety of cancer cells in vitro, including colon, breast, lung, kidney, CNS, blood and skin (Wiley et al., 1995; Ashkenazi et al., 1999; Walczak et al., 1999 Walczak et al., , 2000 Grith et al., 1999) , as well as in colon and breast tumor implants in nude mice (Ashkenazi et al., 1999 , Walczak et al., 1999 . The chemotherapeutic agents 5-FU and CPT-11 can further enhance the cytotoxic eects of TRAIL (Ashkenazi et al., 1999) . At the same time, a large panel of primary human cells including prostate epithelial cells has been tested and reported to be TRAIL resistant (Ashkenazi et al., 1999; Walczak et al., 1999) . Moreover, unlike TNFa and Fas ligand, whose use for cancer therapy had been hampered by their severe toxicity in vivo (Vassalli, 1992; Nagata, 1997) , TRAIL had no toxic eects when systemically administered in rodents (Walczak et al., 1999) and non-human primates (Ashkenazi et al., 1999) . These experimental data lead to the general belief that TRAIL can be used as a safe and speci®c anticancer agent.
Previously, we investigated the eects of TRAIL on several prostate cancer cell lines and found that their responses to TRAIL ranged from being highly sensitive (ALVA-31, DU-145, PC-3) to partially (JCA-1, TSUPr1) or completely (LNCaP) resistant (Nesterov et al., 2001) . Because TRAIL is a potential treatment for human prostate cancer, we next investigated how normal human prostate cells respond to this cytokine.
Incubation of normal human prostate epithelial cells (PrEC) with TRAIL for 6 h induced morphological changes that are characteristic of apoptosis (Figure 1a) , including cell rounding and shrinkage, nuclear condensation, and membrane blebbing. To con®rm that the observed changes constitute apoptosis, we tested whether TRAIL induced DNA fragmentation, a hallmark of apoptotic cell death. Figure 1b demonstrates that treatment of PrEC for 6 h with 100 ng/ml of TRAIL induced signi®cant DNA fragmentation. To quantitate TRAIL-induced DNA fragmentation, we employed an assay that measures the release of free nucleosomes into the cytosol of apoptotic cells. Figure 1c demonstrates that TRAIL-induced DNA fragmentation reaches a maximal level at a TRAIL concentration of 60 ng/ml. Comparing these data with the published results on the sensitivity of various cancer cell lines to TRAIL-induced apoptosis (Ashkenazi et al., 1999; Walczak et al., 1999 Walczak et al., , 2000 Grith et al., 1999) , PrEC could be classi®ed as highly TRAIL-sensitive. Since this ®nding contradicted the general concept that TRAIL toxicity is limited to cancerous cells, we tested whether our preparation of TRAIL possessed an aberrant toxicity toward normal cells. It was found that our TRAIL protein did not cause apoptosis in several other primary cells: human foreskin ®broblasts (HFF), human umbilical cord endothelial cells (HUVEC), and human aorta smooth muscle cells (HASMC) (Figure 1c ). Consistent with previously published data (Ashkenazi et al., 1999; Walczak et al., Figure 1 (a) Normal prostate epithelial cells (PrEC) were pre-treated overnight with 10 mM cycloheximide or left untreated (Control). Cultures were then incubated for 2 h with 100 or 1000 ng/ml of TRAIL, and visualized by light microscopy. (b) PrEC were pre-treated with 10 mM cycloheximide overnight or left untreated. Where indicated, cells were then incubated with 100 ng/ml of TRAIL for 6 h and DNA fragmentation was monitored by electrophoresis in a 2% agarose gel. (c) PrEC, human foreskin ®broblasts (HFF), human umbilical vein endothelial cells (HUVEC), and human aorta smooth muscle cells (HASMC) were incubated for 6 h with TRAIL at concentrations increasing from 7 ± 1000 ng/ml. DNA fragmentation was quantitated by measuring the relative amounts of DNA-histone complexes released into cytoplasm using Cell Death Detection ELISA plus Kit (Roche Diagnostics Corporation, Indianapolis, IN, USA). In one case PrEC were pre-treated overnight with 10 mM cycloheximide prior to the experiment. All primary huamn cells were purchased from Clonetics (Biowhittaker Products, Walkersville, MD, USA) and maintained as outlined by the supplier. The expression and puri®cation of recombinant TRAIL was described in detail elsewhere (Nesterov et al., 2001) . Brie¯y, soluble TRAIL was generated by expression of amino acids 114 ± 281 of human TRAIL fused with amino-terminal (His) 6 tag in yeast Pichia pastoris. The secreted protein was puri®ed to homogeneity from the yeast supernatant by Ni-chelate chromatography (Figure 2a,b) . Thus, contrary to the concept that malignant cells are more sensitive to this protein than normal ones (Wiley et al., 1995; Leverkus et al., 2000) , it appears that cells may either decrease or increase their sensitivity to this agent upon transformation. The ®nding that, unlike some other human primary cells, PrEC appear to be unusually sensitive to TRAIL raised the question of whether these cells contain an abnormally high number of TRAIL receptors. Quantitative PCR data (Figure 2c ) demonstrated that the amount of mRNA for TRAIL receptors DR4 and DR5 in PrEC was comparable to that found in TRAIL-resistant HUVEC and HASMC. However, the proportional amount of mRNA for TRAIL receptors DcR1 and DcR2, which bind TRAIL but do not transduce a death signal, was signi®cantly lower in PrEC and TRAILsensitive prostate cancer cells ALVA-31 than in other primary cells and TRAIL-resistant prostate cancer cells LNCap. Thus, one possible explanation for the unusual sensitivity of PrEC to TRAIL is that these cells have fewer decoy' receptors.
Since our data contradicted the previous report (Ashkenazi et al., 1999) where PrEC were found to be TRAIL-resistant, we performed a series of experiments to con®rm the speci®city of our observation. First, to Figure 2 (a) Normal human prostate epithelial cells on 1st and 5th passages were pre-treated with 10 mM cycloheximide overnight or left untreated. Cells were then incubated for 24 h with TRAIL alone at concentrations increasing from 7 ± 1000 ng/ml or in combination with 40 mM of Z-VAD-FMK (Enzyme Systems Products, Livermore, CA, USA). Cell viability was determined spectrophotometrically using an MTS tetrazolium based assay (Promega, Madison, WI, USA). Absorbance was measured at 490 nm and data from quadruplicate determinations was plotted as per cent of maximal signal. (b) Human prostate cancer cell lines LNCaP and ALVA-31, and renal cancer cell lines ACHN and A498, were incubated for 24 h with TRAIL at concentrations increasing from 7 ± 1000 ng/ml. Cell viability was determined as described in the legend to a. (c) Relative amounts of mRNA for pro-apoptotic TRAIL receptors DR4 and DR5 and`decoy' receptors DcR1 and DcR2 in primary cells and prostate cancer cell lines were determined by quantitative PCR using b-actin as a standard. RNA was extracted from cells using TRIzol reagent (GibcoBRL, Rockville, MD, USA). Real time PCR was performed using iCycler (BioRad, Hercules, CA, USA). (d) PrEC were treated for 36 h with soluble extracellular domain of TRAIL receptor DR5 (DR5:Fc) (Alexis, San Diego, CA, USA) alone at concentrations increasing from 64 to 8000 ng/ml or in the presence of 100 ng/ml of TRAIL. Cell viability was determined as described in the legend to a rule out the possibility that TRAIL produced in our laboratory is signi®cantly more potent than that used by others, we tested its ecacy on two renal cancer cell lines, ACHN and A498 (Figure 2b ), which were also examined by Ashkenazi et al., 1999 . The results we obtained using our TRAIL preparation were comparable to the published data: 100 ng/ml of TRAIL reduced cell viability approximately 2 ± 5-fold for ACHN and A498 cells respectively. Second, using pan-caspase inhibitor Z-VAD-FMK, we con®rmed that the eect of our TRAIL on PrEC was mediated by caspases (Figure 2a) , suggesting that our TRAIL was activating the normal apoptotic pathway. Third, we found that the soluble extracellular domain of TRAIL receptor DR5 (DR5:Fc) is capable of inhibiting TRAIL-induced apoptosis in PrEC (Figure 2d) , indicating that the eect of TRAIL is receptormediated and does not result from a toxic contaminant of our preparation.
Since the response of cells to various apoptotic stimuli may change with aging (Warner et al., 1997) we also tested whether the con¯icting results could arise from the dierences in the age of cell cultures. In our experiments PrEC did not change their growth characteristics during the ®rst ®ve passages, with senescent cells beginning to appear after passage six. The data presented in Figure 2a demonstrate that young (1st passage) and aged (5th passage) cultures are equally sensitive to TRAIL.
It is possible that the discrepancies between our results and those previously published may arise from the assays chosen to quantitate apoptosis. For example, in the apoptosis-speci®c DNA fragmentation assay, internucleosomal DNA fragmentation reached a maximum at a TRAIL concentration of 60 ng/ml (Figure 1c) . However, in the tetrazolium conversion assay, a technique that measures general cell viability (Cory et al., 1991) , the maximal eect could not be achieved even at 1000 ng/ml of TRAIL (Figure 2a ). In the report by Ashkenazi et al., 1999 , PrEC were found to be TRAIL-insensitive, judging by propidium iodide staining. A possible drawback to the use of vital dyes, such as propidium iodide, is that cells undergoing apoptosis may retain cell membrane integrity and appear alive until late in the apoptotic program when secondary necrosis begins (Loo and Rillema, 1998) . For example, in our experiments, staining of PrEC with vital dye, trypan blue, did not detect a signi®cant number of dead cells if they were treated with TRAIL for less than 24 h (data not shown).
The pro-apoptotic eects of TRAIL can often be enhanced by the inhibition of protein synthesis (Grith et al., 1998; Kreuz et al., 2001; Wajant et al., 2000) , suggesting that proteins with a short half-life protect cells from TRAIL-induced death. Therefore, we tested whether the inhibition of protein synthesis by cycloheximide aects TRAIL-induced apoptosis in PrEC. As demonstrated by Figure 1 , cycloheximide had little or no eect on TRAIL-induced morphological changes and only moderately increased sensitivity of cells to this agent in DNA fragmentation assays. However, as measured by the tetrazolium conversion assay (Figure 2a ) which assesses cell viability based on the respiratory function of mitochondria (Cory et al., 1991) , the inhibition of protein synthesis dramatically enhanced TRAIL toxicity. These results suggest that some, but not all TRAIL-induced apoptotic responses in PrEC are partially inhibited by short-lived antiapoptotic proteins. As demonstrated by Figure 3 , processing of the initiator caspase 8, the eector caspase 3, and one of caspase 3 substrates, the inhibitory subunit of DNA fragmentation factor (DFF45/ICAD) (Cryns and Yuan, 1998) , were induced by TRAIL alone as eciently as when TRAIL was combined with cycloheximide. In contrast, cyclohex- Figure 3 PrEC were pre-treated overnight with 10 mM cycloheximide or left untreated. Cultures were then incubated for 6 h with 100 or 1000 ng/ml of TRAIL alone or in combination with cycloheximide. Cell lysates were electrophoresed and the same Western blot was consecutively probed with antibodies speci®c to caspase 8 (Upstate Biotechnology, Lake Placid, NY, USA), caspase 3 (Transduction Laboratories, Lexington, KY, USA), DFF45 (Zymed Laboratories, So. San Francisco, CA, USA), gelsolin (Sigma, St. Louis, MO, USA), FLIP 1 (ABR, Golden, CO, USA) and FLIP g/d (Calbiochem, San Diego, CA, USA) imide signi®cantly enhanced processing of gelsolin, a prominent caspase 3 substrate, implicated in mediating apoptotic cytoskeletal changes (Kothakota et al., 1997) . This result indicates that in PrEC a short-lived anti-apoptotic proteins(s) may inhibit the activity of the eector caspases toward speci®c substrates.
It has been recently reported that the inhibition of protein synthesis signi®cantly enhances TRAIL-induced apoptosis in primary human keratinocytes (Kothakota et al., 1997) . In keratinocytes, cycloheximide down-regulated FLIPs, proteins implicated in caspase 8 inhibition (Tschopp et al., 1998) and accelerated TRAIL-induced caspase 8 processing. However, in PrEC cycloheximide did not aect either the level of FLIPs or the rate of caspase 8 processing (Figure 3 ). This result indicates that the biologic eects of cycloheximide may be cell type speci®c.
Together with the recent data on TRAIL cytotoxicity toward primary human keratinocytes (Leverkus et al., 2000) and hepatocytes (Jo et al., 2000) our results challenge the concept of the cytotoxic eects of TRAIL being limited to transformed cells. While this paper was under review, Lawrence et al., 2001 reported that dierent preparations of TRAIL may have dierent eects on primary cells. Based on the observation that recombinant TRAIL containing a hexahistidine tag induced apoptosis in primary human hepatocytes, whereas TRAIL without this tag did not, the authors concluded that the toxicity of TRAIL toward normal cells depended on the presence of hexahistidine. However, the data on primary human keratinocytes demonstrated that recombinant TRAIL which lacks a hexahistidine sequence may also trigger apoptosis in certain normal cells (Lawrence et al., 2001 ). Since we were not able to obtain TRAIL preparations used in the above referenced studies, we cannot preclude that the toxicity of our TRAIL toward prostate epithelial cells resulted from the presence of a hexahistidine tag. However, the eect of our TRAIL on PrEC did not appear to result from non-speci®c toxicity because: (1) it was dependent on caspase activity; (2) it could be inhibited by the extracellular domain of TRAIL receptor; and (3) it was accompanied by proteolytic events typical of receptor-mediated apoptosis. The observation that PrEC were unusually sensitive to TRAIL may have important implications for TRAILbased prostate cancer therapy. As the majority of prostate cancers are derived from the epithelial cells (Stamey and McNeal, 1992) , it is possible that TRAIL could be used for the treatment of developing premalignant lesions or early stages of prostate cancer. At the same time, our data raise concerns about TRAIL safety when this agent is used as a systemic drug for cancer therapy. It cannot be ruled out that some other human tissues may also be sensitive to this agent; thus, more extensive studies are needed to evaluate TRAIL sensitivity of multiple other primary cell lines before TRAIL is used for human treatment. A better understanding of the mechanisms involved in the inhibition of receptor-mediated cell death may also be bene®cial for deciphering control of TRAIL-induced apoptosis in normal and malignant cells.
